SORRENTO THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 7.01. Regulation FD Disclosure.

On December 6, 2021, Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., issued a press release announcing the signing of a letter of intent for a potential business combination with Vickers Vantage Corp I, a Cayman Islands corporation (NASDAQ: VCKA). A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Item 7.01 and Exhibit 99.1 furnished as part of Item 9.01 of this Current Report on Form 8-K is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.



  99.1     Press Release, dated December 6, 2021.
104      Cover Page Interactive Data File, formatted in Inline Extensible Business
         Reporting Language (iXBRL).

© Edgar Online, source Glimpses